Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Brokerages

Savara Inc (NASDAQ:SVRA) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.83.

A number of research firms have recently weighed in on SVRA. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Savara in a report on Friday, March 28th. Finally, Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company.

Savara Stock Performance

Shares of SVRA opened at $3.01 on Friday. The company has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $3.10. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market capitalization of $519.63 million, a PE ratio of -7.00 and a beta of 0.52. Savara has a one year low of $2.26 and a one year high of $5.31.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. On average, analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently made changes to their positions in the company. Cibc World Markets Corp bought a new position in Savara in the 4th quarter valued at approximately $33,000. XTX Topco Ltd bought a new position in shares of Savara during the fourth quarter valued at $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Savara during the fourth quarter valued at $37,000. KLP Kapitalforvaltning AS bought a new stake in Savara in the 4th quarter worth about $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara in the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.